Clinical Trials Browser

Completed × Waldenstrom Macroglobulinemia × carfilzomib × Clear all

Waldenstrom Macroglobulinemia

NCT01470196 2018-11-20

CaRD

Phase 2 Completed

31 enrolled 10 charts

Lymphoid

Waldenstrom Macroglobulinemia

NCT02142530 2018-01-25

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

Phase 1 Completed

19 enrolled

Lymphoid

Lymphoma, Follicular, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell

NCT00150462 2017-05-02

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies

Phase 1 Completed

48 enrolled 26 charts

LymphoidPlasma cell

Hodgkin Disease, Lymphoma, Lymphoma, Non-Hodgkin, Waldenstrom Macroglobulinemia, Multiple Myeloma, Neoplasms, Plasma Cell

Clinical Trials

A Phase II Study of Carfilzomib in Relapsed Waldenström's Macroglobulinemia (WM) IST-CAR-531

CaRD

Carfilzomib Plus Belinostat in Relapsed/Refractory NHL

Safety Study of the Proteasome Inhibitor PR-171 (Carfilzomib for Injection) in Patients With Hematological Malignancies